Nuvalent

We’re proud to support the @DAVAOnc 4th Summit on Thoracic Malignancies, which brings together global experts in #LungCancer research and care. We look forward to engaging discussions, expert insights, and new approaches shaping the future of thoracic oncology.

Today, on #ClinicalTrialsDay, we honor patients, caregivers, investigators, and research teams who make clinical trials possible. Your courage drives our commitment to developing #PreciselyTargetedTherapies for people living with #cancer. Thank you for making progress possible.

We’re excited to announce the initiation of ALKAZAR—our global, pivotal Phase 3 trial evaluating neladalkib in TKI-naïve patients with #ALK+ #NSCLC. This marks a key step toward our goal of bringing neladalkib to the front line of ALK+ lung cancer care. investors.nuvalent.com/2025-07-21-Nuv…

We’re heading to San Diego as a proud sponsor of this year’s @ALKPositiveinc Summit! We look forward to connecting with patients, caregivers, and healthcare experts as we explore the latest in #ALK+ NSCLC research and cancer care. Register: secure.qgiv.com/for/alksummit2… #ALKSummit25

Last week, some of our #NuCrew colleagues swapped their office chairs for running shoes and hit the pavement at the Boston @jpmorgan Corporate Challenge! From walkers to runners, first-timers to seasoned athletes, our team showed up with energy and a shared commitment to wellness

Today, we shared positive topline results for zidesamtinib in TKI pre-treated patients with advanced ROS1+ NSCLC from our global Phase 1/2 ARROS-1 clinical trial. Learn more here: investors.nuvalent.com/2025-06-24-Nuv…

⚡️TUNE IN TOMORROW: Pivotal data for TKI pre-treated patients with advanced ROS1+ NSCLC from our ARROS-1 clinical trial of zidesamtinib is coming. Join our live webcast & conference call on June 24, 2025 at 8:00am ET. Learn more: investors.nuvalent.com/2025-06-23-Nuv…

Welcome Christy Oliger to our board of directors! Her success in delivering new therapies to patients living with cancer adds valuable perspective as we prepare for a potential first approval in 2026 from our pipeline of #PreciselyTargetedTherapies. investors.nuvalent.com/2025-06-18-Nuv…

At Nuvalent, our work is inspired by the strength, resilience, and courage of people living with #cancer. This June we’re proud to recognize #ALKAwarenessMonth and stand with @ALKPositiveinc — a community that embodies what it means to be #PoweredByPatients.

What a game! The #NuCrew had an unforgettable time at @BioBall_MA 2025. Thank you to @SpOlympicsMA for an amazing day of teamwork, sportsmanship, and fun. Already counting down to next year! 🏀

That’s a wrap on #ASCO25! Grateful to connect with the #OncologyCommunity and share our work towards advancing #PreciselyTargetedTherapies for people living with #cancer. Thanks to all who stopped by—we’re energized by the conversations and ready to carry the momentum forward.

On #NationalCancerSurvivorsDay, we honor the strength, resilience & hope of #CancerSurvivors everywhere. Our work to develop #PreciselyTargetedTherapies is inspired by the goal of creating more survivorship stories. We stand with all patients, caregivers & loved ones. #NCSD2025

We’re looking forward to connecting with colleagues across the #OncologyCommunity at #ASCO25! Stop by our "Trial in Progress" posters to meet the team and learn more about our ALKAZAR and HEROEX-1 studies for #ALK and #HER2 #NSCLC: Learn more: investors.nuvalent.com/2025-04-23-Nuv…

Conference season is in full swing and the #NuCrew has been sharing ideas and insights at meetings in the US and abroad this spring. 🌸

HOT JOB ALERT 🚨 Senior Manager, GCP, Quality Assurance🚨 Interested in joining the #NuCrew? Learn more about this role and other new opportunities here: nuvalent.com/jobs/?gh_jid=5… #NuTalent #hiring #biotech

Meet the #NuTalent on the #NuCrew! Join us in welcoming Ge, Lauren, Yadilka, and Patrick to the team. We’re thrilled to have you all on board!

This morning we reported our Q1 2025 financial results alongside recent business & pipeline progress. Highlights include continued progress toward planned milestones & key internal promotions that strengthen our leadership team. Read more: investors.nuvalent.com/2025-05-08-Nuv… $NUVL #biotech

Our latest manuscript has been published in @MCT_AACR, highlighting preclinical data supporting the molecular design of #zidesamtinib, our novel and selective ROS1, & providing key structural insights into how the ROS1 G2032R mutation impacts TKI binding. aacrjournals.org/mct/article/do…

Find us today at #AACR2025! We will be presenting the first crystal structure of ROS1 G2032R, a known resistance mutation that occurs in ROS1-positive #NSCLC, which supports zidesamtinib’s rational molecular design as a novel ROS1-selective inhibitor. nuvalent.com/wp-content/upl…

Our team is at #AACR2025! Be sure to visit our poster on #neladalkib (NVL-655), which includes new data that reinforce its differentiated preclinical profile, during this morning’s session. Learn more: nuvalent.com/wp-content/upl… #Nuvalent #biotech #preclinicaldata